MLYS
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 43.76 · operating margin 0.0%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Interesting trend — weekly bias down
VENTE TOTALE: 3 000 titres (~85 740,00 $ US)
- Insiders
- Karydas Daphne
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$85,740
Avg sell (VWAP, 90d window) $26.46 vs last close $25.86 (-2.3%)
- Last activity
- 2026-09-15
- Liquidity
- Liquid $36,461,068/day · 20d vol
- Last synced
-
2026-09-25 21:10:40
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-21 | Warren Eric | Sell | 7,438 | $28.12 | $209,136 | Form 4 |
| 2026-09-15 | Karydas Daphne | Sell | 3,000 | $28.58 | $85,740 | Form 4 |
| 2026-08-21 | Warren Eric | Sell | 7,437 | $25.98 | $193,189 | Form 4 |
| 2026-08-10 | Rodman David Malcom | Sell | 2,170 | $27.09 | $58,785 | Form 4 |
| 2026-07-21 | Warren Eric | Sell | 7,438 | $26.87 | $199,885 | Form 4 |
| 2026-07-17 | Rodman David Malcom | Sell | 416 | $26.53 | $11,036 | Form 4 |
| 2026-07-15 | Rodman David Malcom | Sell | 6,349 | $26.61 | $168,955 | Form 4 |
| 2026-07-13 | Congleton Jon | Sell | 10,700 | $27.24 | $291,441 | Form 4 |
| 2026-07-13 | Rodman David Malcom | Sell | 14,058 | $27.58 | $387,717 | Form 4 |
| 2026-07-09 | Rodman David Malcom | Sell | 2,171 | $30.30 | $65,781 | Form 4 |
| 2026-06-30 | Congleton Jon | Sell | 17,000 | $26.82 | $455,896 | Form 4 |
| 2026-06-26 | Warren Eric | Sell | 104,124 | $25.90 | $2,696,322 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-21
MLYS presents a deeply concerning financial profile with zero revenue, persistent negative profitability across all return metrics, and a fully cash-burning, pre-commercial business model that undermines the high…
The first sentence of the analysis written for MLYS on 2026-09-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 43.763 | 14.021 | 23.765 | 13.984 | 2.201 | |
| Quick Ratio | 43.763 | 14.021 | 23.765 | 13.984 | 2.201 | |
| Solvency Ratio | -10.229 | -12.138 | -6.859 | -0.179 | -0.570 | |
| Cash Ratio | 11.442 | 7.790 | 4.704 | 10.872 | 2.100 | |
| Price To Earnings Ratio | -15.847 | -3.363 | -4.322 | -3.196 | -4.740 | |
| Price To Earnings Growth Ratio | 0.423 | -0.040 | 0.066 | -0.066 | -0.011 | |
| Forward Price To Earnings Growth Ratio | 0.423 | -0.040 | 0.066 | -0.066 | -0.011 | |
| Price To Earnings Diluted Ratio | -15.847 | -3.363 | -4.322 | -3.196 | -4.740 | |
| Price To Earnings Diluted Growth Ratio | 0.423 | -0.040 | 0.066 | -0.066 | -0.011 | |
| Price To Book Ratio | 3.797 | 3.124 | 1.291 | -1.823 | -4.009 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -17.238 | -3.591 | -3.834 | -3.261 | -6.313 | |
| Price To Operating Cash Flow Ratio | -17.240 | -3.593 | -3.834 | -3.261 | -6.313 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.023 | 1.077 | 1.043 | -2.189 | -0.485 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -9.423 | -11.356 | -7.744 | -3.622 | -2.881 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -16.780 | -717.815 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -18.782 | -693.519 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -9,494.400 | -1,732.438 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -9,494.400 | -1,732.438 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -14.764 | -2.719 | -3.643 | -0.269 | -4.194 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 43.763 | ▲29.742 | ▲24.216 |
| Quick Ratio | 43.763 | ▲29.742 | ▲24.216 |
| Solvency Ratio | -10.229 | ▲1.909 | ▼-4.234 |
| Cash Ratio | 11.442 | ▲3.652 | ▲4.061 |
| Price To Earnings Ratio | -15.847 | ▼-12.484 | ▼-9.553 |
| Price To Earnings Growth Ratio | 0.423 | ▲0.463 | ▲0.349 |
| Forward Price To Earnings Growth Ratio | 0.423 | ▲0.463 | ▲0.349 |
| Price To Earnings Diluted Ratio | -15.847 | ▼-12.484 | ▼-9.553 |
| Price To Earnings Diluted Growth Ratio | 0.423 | ▲0.463 | ▲0.349 |
| Price To Book Ratio | 3.797 | ▲0.672 | ▲3.321 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -17.238 | ▼-13.648 | ▼-10.391 |
| Price To Operating Cash Flow Ratio | -17.240 | ▼-13.647 | ▼-10.392 |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.023 | ▼-0.053 | ▲0.930 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -9.423 | ▲1.932 | ▼-2.418 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | -0.000 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲146.919 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲142.460 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Capital Expenditure Coverage Ratio | -9494.400 | ▼-7761.962 | ▼-7249.033 |
| Dividend Paid And Capex Coverage Ratio | -9494.400 | ▼-7761.962 | ▼-7249.033 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -14.764 | ▼-12.044 | ▼-9.646 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.46B | $597.5M | $311.2M | $95.3M | $91.9M | |
| Enterprise value | $2.28B | $483.4M | $261.9M | $7.6M | $81.3M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -16.03x | -2.91x | -3.23x | -0.26x | -5.58x | |
| EV / Free cash flow | -16.02x | -2.90x | -3.23x | -0.26x | -5.58x | |
| EV / EBITDA | -14.76x | -2.72x | -3.64x | -0.27x | -4.19x | |
| Net debt / EBITDA | 1.12x | 0.64x | 0.69x | 3.12x | 0.55x | |
| Current ratio | 43.76x | 14.02x | 23.77x | 13.98x | 2.20x | |
| Income quality | 0.92x | 0.94x | 1.13x | 0.98x | 0.75x | |
| Graham net-net | $9 | $4 | $6 | -$11 | -$5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 106.0% | 100.1% | |
| Working capital | $646.3M | $190.7M | $238.6M | $104.7M | $6.1M | |
| Invested capital | $646.3M | $190.8M | $238.6M | $104.7M | $6.1M | |
| Return on assets | -23.4% | -86.4% | -28.6% | -26.0% | -174.5% | |
| Operating ROA | -39.3% | -84.1% | -46.3% | -50.1% | -297.0% | |
| Return on tangible assets | -23.4% | -86.4% | -28.6% | -26.0% | -174.5% | |
| Return on equity | -23.9% | -93.0% | -29.8% | 57.0% | 84.7% | |
| Return on invested capital | -26.4% | -100.6% | -35.1% | -29.6% | -308.4% | |
| Return on capital employed | -26.4% | -100.6% | -35.1% | -29.6% | -308.4% | |
| Earnings yield | -6.3% | -29.8% | -23.1% | -31.3% | -21.1% | |
| Free cash flow yield | -5.8% | -27.9% | -26.1% | -30.7% | -15.8% | |
| Capex / Op. cash flow | -0.0% | -0.1% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 25.4% | 223.3% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+310.9%EV / Sales n/aEV / EBITDA ▼-442.9%EV / Op. cash flow ▼-13.119Earnings yield ▲+0.235
Profitability
Return on equity ▲+0.691Return on assets ▲+0.630Return on invested capital ▲+0.742Return on capital employed ▲+0.742Operating ROA ▲+0.448Income quality ▼-0.014Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+29.742Net debt / EBITDA ▲+0.477Working capital ▲+455568000.000Invested capital ▲+455553000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+2571.5%EV / Sales n/aEV / EBITDA ▼-252.0%EV / Op. cash flow ▼-10.442Earnings yield ▲+0.148
Profitability
Return on equity ▼-1.086Return on assets ▲+1.511Return on invested capital ▲+2.821Return on capital employed ▲+2.821Operating ROA ▲+2.576Income quality ▲+0.171Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+41.562Net debt / EBITDA ▲+0.571Working capital ▲+640205000.000Invested capital ▲+640243000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-20 Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total transaction of $85,740.00. Following the transaction, the director owned 6,200 shares in the company, valued at approximately $177,196.
- 2026-09-09 Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys'' Board of Directors granted inducement stock option awards covering an aggregate of 29,760 shares and inducement restricted stock unit awards covering an aggregate of 22,320 shares of Mineralys common stock to two new non-executive employees.
- 2026-09-07 Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYS Greenland Capital Management LP reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 64.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,000 shares of the company''s stock after selling 53,500 shares during the period. Greenland Capital Management LP''s holdings
- 2026-09-03 Mineralys: Why I''m Making Stock A Buy Ahead Of Hypertension Approval Decision Mineralys Therapeutics, Inc. is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca''s first-mover advantage with Baxfendy, MLYS''s focused strategy and robust funding position it to capture significant hypertension market share. Lorundrostat demonstrates competitive efficacy and safety, with potential for blockbuster revenues and future label expansion beyond blood pressure reduction.
- 2026-09-01 Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS Canada Pension Plan Investment Board bought a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 51,400 shares of the company''s stock, valued at approximately $1,387,000. Canada Pension Plan Investment Board owned 0.06%
- 2026-08-29 BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,887,038 shares of the company''s stock, valued at approximately $158,832,000. BlackRock Inc. owned approximately 7.14% of Mineralys Therapeutics
- 2026-08-26 Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.
- 2026-08-13 Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys'' Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys'' newly appointed Chief Medical Officer.
- 2026-08-12 Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
- 2026-08-11 Mineralys Therapeutics Q2 Earnings Call Highlights Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.